http://www.thedoctorschannel.com/video/3586.html

The 13-valent pneumococcal conjugate vaccine is as effective as the 7-valent vaccine, which it replaces, in protecting against disease caused by the original seven pneumococcal serotypes and should provided further protection against the six additional serotypes, a multicenter team reports.

The new pneumococcal vaccine (PCV13), also known by the brand name Prevnar 13 (Wyeth), was licensed by the US Food and Drug Administration in February 2010 for prevention of invasive pneumococcal disease caused by the 13 pneumococcal serotypes covered by the vaccine in children aged 6 weeks to 71 months.

One of the pivotal studies of the immunogenicity and safety of PCV13 in infants and toddlers appears in the September issue of Pediatrics, released August 23.